Insulet (NASDAQ:PODD) Stock Gets Price Target Bump from Royal Bank Of Canada

Insulet (NASDAQ:PODD) had its price target hoisted by equities researchers at Royal Bank Of Canada from $160.00 to $180.00 in a report released on Thursday, Benzinga reports. The firm presently has an “outperform” rating on the medical instruments supplier’s stock. Royal Bank Of Canada‘s price target points to a potential upside of 22.86% from the company’s previous close.

Other equities research analysts have also recently issued reports about the company. Stifel Nicolaus lowered their price objective on Insulet from $225.00 to $180.00 and set a “buy” rating on the stock in a research note on Thursday, August 6th. Leerink Partners lowered shares of Insulet from an “outperform” rating to a “market perform” rating and cut their target price for the stock from $247.00 to $145.00 in a research report on Thursday, August 6th. Robert W. Baird set a $175.00 target price on shares of Insulet in a research note on Thursday, August 6th. Raymond James Financial reissued an “outperform” rating and issued a $180.00 price target on shares of Insulet in a research report on Thursday, August 6th. Finally, Jefferies Financial Group restated a “buy” rating and set a $200.00 price target on shares of Insulet in a research note on Wednesday. Twelve equities research analysts have rated the stock with a Buy rating, twelve have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Hold” and an average price target of $185.38.

Insulet Stock Performance

NASDAQ PODD traded down $9.61 on Thursday, hitting $146.51. 1,567,721 shares of the stock traded hands, compared to its average volume of 1,380,594. The company has a debt-to-equity ratio of 0.65, a quick ratio of 1.83 and a current ratio of 2.48. The business’s fifty day moving average is $141.97 and its two-hundred day moving average is $176.65. Insulet has a 12 month low of $126.40 and a 12 month high of $354.88. The firm has a market capitalization of $10.16 billion, a price-to-earnings ratio of 23.86, a PEG ratio of 1.21 and a beta of 1.06.

Insulet (NASDAQ:PODD) last issued its earnings results on Wednesday, November 4th. The medical instruments supplier reported $1.99 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.59 by $0.40. Insulet had a return on equity of 29.29% and a net margin of 12.29%. The firm had revenue of $842.00 million for the quarter, compared to analyst estimates of $832.63 million. During the same period in the previous year, the company posted $1.24 earnings per share. The business’s revenue was up 19.2% on a year-over-year basis. As a group, equities analysts anticipate that Insulet will post 6.75 EPS for the current fiscal year.

Hedge Funds Weigh In On Insulet

Hedge funds have recently made changes to their positions in the stock. Allworth Financial LP raised its stake in shares of Insulet by 2.3% during the 3rd quarter. Allworth Financial LP now owns 3,104 shares of the medical instruments supplier’s stock valued at $405,000 after purchasing an additional 71 shares during the period. State of Wyoming boosted its stake in Insulet by 34.6% in the 1st quarter. State of Wyoming now owns 284 shares of the medical instruments supplier’s stock worth $60,000 after purchasing an additional 73 shares during the period. American Trust boosted its stake in Insulet by 8.6% in the 1st quarter. American Trust now owns 1,180 shares of the medical instruments supplier’s stock worth $248,000 after purchasing an additional 93 shares during the period. Basecamp Wealth Advisors LLC increased its holdings in shares of Insulet by 48.3% in the first quarter. Basecamp Wealth Advisors LLC now owns 313 shares of the medical instruments supplier’s stock worth $66,000 after purchasing an additional 102 shares during the period. Finally, Elevation Wealth Partners LLC increased its holdings in shares of Insulet by 115.6% in the third quarter. Elevation Wealth Partners LLC now owns 194 shares of the medical instruments supplier’s stock worth $25,000 after purchasing an additional 104 shares during the period.

Key Stories Impacting Insulet

Here are the key news stories impacting Insulet this week:

• Positive Sentiment: Several firms raised targets and maintained bullish ratings: RBC lifted its target to $180 and kept an Outperform rating, Bernstein raised its target to $200 and kept Outperform, and Canaccord reiterated Buy with a $179 target. RBC target update Canaccord rating update
• Positive Sentiment: Other analysts also raised targets, while commentary described Insulet as potentially undervalued and highlighted its $1 billion buyback. Recent quarterly results provide support: the company beat earnings and revenue estimates, with revenue up 19.2% year over year, according to the supplied company data. Valuation and buyback article
• Neutral Sentiment: UBS, JPMorgan, Citi, Barclays, Wells Fargo and Leerink all increased their price targets, generally retaining Neutral, Equal Weight or Market Perform ratings. The higher targets are supportive, but the largely unchanged ratings suggest analysts see risks as well as recovery potential.
• Negative Sentiment: Analyst discussion flagged a more conservative 2027 outlook and competition, tempering optimism about Insulet’s growth. Coverage characterized the outlook as moderate despite international strength and an innovation pipeline. RBC outlook article Q3 growth analysis

About Insulet

Insulet Corporation is a medical device company that develops, manufactures and sells wearable, tubeless insulin delivery systems for people with insulin-dependent diabetes. Its products are designed to provide an alternative to traditional insulin injections and conventional tubed insulin pumps.

The company’s primary product platform is Omnipod, which includes the disposable, wearable Pod and a handheld controller or compatible smartphone-based application. Omnipod products include the Omnipod DASH system and the Omnipod 5 Automated Insulin Delivery System, which is designed to integrate with compatible continuous glucose monitoring technology to help automate insulin delivery.